Intestinal research
Cure8 research brief
Why This Matters
If confirmed, differences between tirzepatide and GLP-1RAs could influence medication choice for people with IBD who need weight-loss or glucose-lowering therapy. Reduced IV steroid use suggests fewer severe flares requiring inpatient steroids.
Who Should Pay Attention
Adults with IBD (including ulcerative colitis) considering or taking tirzepatide or GLP-1RAs; gastroenterologists and endocrinologists managing metabolic therapy in patients with IBD; clinical researchers planning prospective studies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study used a retrospective, propensity-matched U.S. database to compare outcomes for patients with IBD prescribed tirzepatide versus GLP-1 receptor agonists (GLP-1RAs).
Over a median follow-up of about 18 months, tirzepatide was associated with a lower risk of intravenous steroid use and a lower risk on a composite IBD outcome (IV steroids or intestinal surgery), while risks of hospitalization, ED visits, intestinal surgery, and adverse outcomes were similar between groups.
The analysis included 3,042 matched patients per group and reported adjusted hazard ratios for IV steroid use (aHR 0.81) and the composite outcome (aHR 0.86). The authors note similar findings in a subgroup with ulcerative colitis.
Because this is a retrospective observational study using administrative/clinical data, the results show association not causation and may be affected by unmeasured confounding. Prospective studies are needed to confirm whether tirzepatide has a true protective effect on IBD activity and to investigate possible biological mechanisms.
Keep In Mind
This report is based on a retrospective, propensity-matched analysis of observational data from 2022–2025. Observational designs can adjust for measured factors but cannot prove causality. The article calls for prospective studies to validate findings and explore mechanisms.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationIntestinal research
AuthorsKrishan S Patel, Butros Fakhoury, Kavin Parmar +4 more
InstitutionDepartment of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 10, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...
Safety of ozanimod and etrasimod in ulcerative colitis
People with ulcerative colitis considering or taking ozanimod or etrasimod may want to know about potential adverse events reported after these drugs entered the market, especially for nervous‑system, eye, and cardiac...
Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea.
Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...